Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) had its price objective boosted by stock analysts at Wells Fargo & Company from $30.00 to $42.00 in a report released on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Wells Fargo & Company‘s price target would indicate a potential upside of 45.08% from the company’s previous close.

A number of other research firms have also commented on KNSA. Jefferies Financial Group lifted their price objective on Kiniksa Pharmaceuticals International from $40.00 to $45.00 and gave the stock a “buy” rating in a research note on Tuesday, April 29th. Wall Street Zen raised Kiniksa Pharmaceuticals International from a “hold” rating to a “buy” rating in a research note on Sunday, July 6th. Citigroup started coverage on Kiniksa Pharmaceuticals International in a research note on Thursday, March 13th. They issued a “buy” rating and a $40.00 price objective on the stock. Finally, Wedbush reiterated an “outperform” rating and issued a $34.00 target price on shares of Kiniksa Pharmaceuticals International in a report on Wednesday, April 16th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, Kiniksa Pharmaceuticals International currently has an average rating of “Buy” and a consensus target price of $39.33.

Kiniksa Pharmaceuticals International Trading Up 0.5%

Shares of KNSA stock opened at $28.95 on Wednesday. The business’s 50-day moving average price is $27.71 and its 200-day moving average price is $23.10. Kiniksa Pharmaceuticals International has a 12 month low of $17.82 and a 12 month high of $30.69. The firm has a market capitalization of $2.11 billion, a price-to-earnings ratio of -115.80 and a beta of 0.05.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings data on Tuesday, April 29th. The company reported $0.11 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.09. The company had revenue of $137.79 million for the quarter, compared to analyst estimates of $128.35 million. Kiniksa Pharmaceuticals International had a negative return on equity of 3.83% and a negative net margin of 3.52%. The firm’s quarterly revenue was up 72.5% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.25) earnings per share. On average, sell-side analysts predict that Kiniksa Pharmaceuticals International will post -0.55 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, insider Ross Moat sold 27,594 shares of Kiniksa Pharmaceuticals International stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $29.02, for a total value of $800,777.88. Following the completion of the sale, the insider owned 9,415 shares of the company’s stock, valued at approximately $273,223.30. This trade represents a 74.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO Eben Tessari sold 17,300 shares of the company’s stock in a transaction on Monday, June 16th. The stock was sold at an average price of $28.28, for a total transaction of $489,244.00. Following the transaction, the chief operating officer owned 61,563 shares in the company, valued at approximately $1,741,001.64. The trade was a 21.94% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 440,863 shares of company stock worth $12,101,029 over the last three months. Insiders own 53.48% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in KNSA. GAMMA Investing LLC raised its holdings in shares of Kiniksa Pharmaceuticals International by 84.8% in the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company’s stock worth $27,000 after acquiring an additional 568 shares during the last quarter. US Bancorp DE bought a new stake in Kiniksa Pharmaceuticals International during the 1st quarter worth approximately $33,000. Asset Management One Co. Ltd. purchased a new stake in shares of Kiniksa Pharmaceuticals International in the first quarter worth approximately $41,000. Wealthquest Corp purchased a new stake in shares of Kiniksa Pharmaceuticals International in the first quarter worth approximately $42,000. Finally, Lazard Asset Management LLC purchased a new position in shares of Kiniksa Pharmaceuticals International during the fourth quarter valued at approximately $61,000. 53.95% of the stock is currently owned by institutional investors and hedge funds.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.